The Nigerian Investor
TNI Research

Market Analysis

In-depth analysis of NGX-listed companies by TNI Research. We read the quarterly, half-year and full-year results, so you can see what's driving revenue, profit, cash and dividends, and what to watch next.

Every article shows its sources and separates reported figures from our calculations.

MARKET NOTE · NGX WEEKLY · WEEK ENDED 13 NOVEMBER 2026

NGX Weekly Wrap: The Market Rose 1.36% This Week. Here's What Really Happened

The All-Share Index gained 1.36%, but the rise came on one day and from a few big companies. The week explained in plain English.

13 November 2026 · Read analysis →
Sector scorecard · Pharmaceuticals · 9M 2026

Nigerian Pharma 9M 2026 Scorecard: May & Baker Wins on Quality, Fidson on Scale, MeCure Carries the Debt

A calmer naira and lower FX losses lifted every listed drugmaker in 2026. Only May & Baker turned that into clean, cash-backed, cheaply priced earnings.

9 November 2026 · Read analysis →
Fidson Healthcare Plc (FIDSON) · Pharmaceuticals · 9M 2026

Fidson 9M 2026: Profit Up 47%, but FX Did Most of the Heavy Lifting

Fidson's 9M profit jumped 47% to N11.74bn, but about 69% of the pre-tax gain came from vanished FX losses while receivables and debt ballooned.

9 November 2026 · Read analysis →
MeCure Industries Plc (MECURE) · Pharmaceuticals · 9M 2026

MeCure 9M 2026: Operations Fire, but the Bank Takes Half

MeCure's EBIT jumped 34% to N17.5bn, but N8.8bn of finance costs, N55bn of net debt and a 28x P/E make it the sector's highest-risk growth story.

9 November 2026 · Read analysis →
May & Baker Nigeria Plc (MAYBAKER) · Pharmaceuticals · 9M 2026

May & Baker 9M 2026: A 10-Point Margin Leap, Net Cash and a Single-Digit P/E

May & Baker's PAT rose 76% to N5.89bn on a 10ppt gross-margin jump. It holds net cash and trades near 9.7x trailing earnings, the best value in listed pharma.

9 November 2026 · Read analysis →